Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Plasma fibroblast growth factor-21 levels in patients with inborn errors of metabolism. Molecular genetics and metabolism reports Kirmse, B., Cabrerra-Luque, J., Ayyub, O., Cusmano, K., Chapman, K., Summar, M. 2017; 13: 52-54

Abstract

Fibroblast growth factor-21 (FGF21) levels are elevated in patients with primary mitochondrial disorders but have not been studied in patients with inborn errors of metabolism (IEM) known to have secondary mitochondrial dysfunction. We measured plasma FGF21 by ELISA in patients with and without IEM. FGF21 levels were higher in patients with IEM compared to without IEM (370 pg/dL vs. 0-65 pg/dL). Further study of FGF21 as a biomarker in IEM is warranted.

View details for DOI 10.1016/j.ymgmr.2017.04.001

View details for PubMedID 28920014

View details for PubMedCentralID PMC5586549